COVID-19：抗体鸡尾酒疗法被批准为“预防药物”：RONA PREVE
-针对轻症患者的“RONA PREVE”-
“抗体鸡尾酒疗法”：
“抗体鸡尾酒疗法”用于治疗新型冠状病毒的轻症患者。
厚生劳动省审议会：
我们已同意将其用作无症状人群的第一种“预防药物”。
“RONA PREVE”适用于轻症患者：
中外制药用于抗体鸡尾酒疗法的“Ronapreve”已获得理事会批准。
被批准为“电晕预防”
今年7月，它被特别批准为有加重风险的轻中度患者的“治疗药物”。
以“防患于未然”为新宗旨，扩大管理范围。
中外
在临床试验中
在家中密切接触患上这种疾病的风险降低了 81%。
检测呈阳性且无症状的人患上这种疾病的风险降低了 31%。
此外，静脉滴注形式的抗体鸡尾酒疗法也被批准用于皮下注射。
NTV新闻24
https://www.news24.jp/articles/2021/11/04/07968978.html
Japan to use antibody cocktail to prevent symptoms
Japan’s health ministry
is to expand the use of a so-called antibody cocktail to prevent COVID-19 symptoms in patients’ families and others.
The ministry approved in July
the intravenous use of the antibody cocktail, which combines two types of antibodies, for patients with mild to moderate symptoms that could become severe.
Chugai Pharmaceutical,
the drug’s distributor in Japan,
had applied for expanding its use to include prevention.The company cited the results of overseas clinical trials
that show an 81 percent reduction in the risk of symptomatic coronavirus infections among people who were in close contact with infected family members.
On Thursday,
an expert panel approved the ministry’s policy to use the antibody cocktail for household exposure and asymptomatic cases.But it added that
the use in principle must be limited to those who are at risk of developing severe symptoms if infected.The panel stressed that
vaccination is the first line of defense for any infectious disease and limited the cocktail’s use to those who may not fully benefit from vaccination.It also agreed to subcutaneous administration, which takes less time than intravenous infusion.
The ministry is set to give formal approval on Friday,
after which the antibody cocktail will be the first drug approved in Japan to prevent COVID-19 symptoms.
NHK WORLD-JAPAN News